Dec 8, 2025 07:00AM
Dec 8, 2025 07:00AM
Nov 3, 2025 04:00PM
Nov 3, 2025 04:00PM
Nov 3, 2025 04:00PM
Oct 29, 2025 07:00AM
Sep 17, 2025 07:00AM BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
Jun 12, 2025 12:30PM
May 19, 2025 12:30PM
Apr 3, 2025 07:00AM
Mar 19, 2025 07:00AM
Mar 12, 2025 01:54PM
Mar 7, 2025 08:00AM
Feb 27, 2025 07:00AM On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
Jan 16, 2025 07:00AM
Dec 6, 2024 12:00PM
Nov 26, 2024 07:00AM
Nov 20, 2024 07:00AM
Nov 14, 2024 12:46PM
Sep 23, 2024 07:00AM
Aug 16, 2024 05:36AM Citi Reiterates Buy Rating on UCB SA (UCB:BB) (UCBJY)
Jun 24, 2024 07:00AM
Jun 20, 2024 08:00AM
May 23, 2024 07:00AM
Apr 12, 2024 07:00AM
Apr 4, 2024 07:00AM
Feb 28, 2024 07:03AM
Jan 3, 2024 07:00AM ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positiv
Dec 8, 2023 02:30PM
Dec 2, 2023 07:00AM
Dec 1, 2023 07:00AM
Nov 14, 2023 07:00AM
Nov 1, 2023 07:00AM
Oct 31, 2023 07:00AM
Oct 18, 2023 07:00AM BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Oct 17, 2023 06:34PM
Oct 13, 2023 12:00PM
Oct 12, 2023 12:20PM
Oct 4, 2023 01:06PM
Jul 21, 2023 07:00AM
Jun 27, 2023 07:00AM
Apr 20, 2023 07:00AM UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting
Apr 17, 2023 07:14AM
Mar 18, 2023 02:10PM
Mar 16, 2023 07:00AM
Jan 18, 2023 07:00AM
Jan 6, 2023 07:00AM
Dec 9, 2022 07:02AM
Dec 9, 2022 07:00AM UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa
Dec 7, 2022 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All